Sequence 9 from Patent US 20070293424

General Information


DRACP ID  DRACP01303

Peptide Name   Sequence 9 from Patent US 20070293424

Sequence  QGGGGWGQPHGGGWG

Sequence Length  15

UniProt ID  B5SY89  Q5UJG1  Q5UJH8  P40242  Q6EH52  Q5UJG3  P49927  B0FYL5  P52114  P40244  P52113  P23907  Q95M08  P67986  Q5XVM4  O18754  P47852  P79141  O46501  P40256  P61766  P67992  P40257  P04156  P40251   

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Antimicrobial, Antitumor, Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01303

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C61H79N21O18

Absent amino acids  ACDEFIKLMNRSTVY

Common amino acids  G

Mass  164434

Pl  7.55

Basic residues  1

Acidic residues  0

Hydrophobic residues  2

Net charge  1

Boman Index  -262

Hydrophobicity  -114.67

Aliphatic Index  0

Half Life 
  Mammalian: 3.5 hour
  Yeast: 10 min
  E.coli: >10 hour

Extinction Coefficient cystines  11000

Absorbance 280nm  785.71

Polar residues  9

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2007/0293424 A1

Patent Title  Antitumoral and Antiviral Peptides.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: EP, RU, AU, ZA, US, WO; Legal Status: Active; Application No: 58571504 ; Filed:Dec 30, 2004; Published: Dec 20, 2007; Earliest Priority: Jan 15, 2004; Granted: Feb 12, 2013

Other Published ID  EP1705182A1  EP1705182A4  EP1705182B1  US8372406  WO2005068491A1 




DRACP is developed by Dr.Zheng's team.